These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29036300)

  • 1. Bayesian hierarchical modeling based on multisource exchangeability.
    Kaizer AM; Koopmeiners JS; Hobbs BP
    Biostatistics; 2018 Apr; 19(2):169-184. PubMed ID: 29036300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Borrowing from supplemental sources to estimate causal effects from a primary data source.
    Boatman JA; Vock DM; Koopmeiners JS
    Stat Med; 2021 Oct; 40(24):5115-5130. PubMed ID: 34155662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calibrated dynamic borrowing using capping priors.
    Ling SX; Hobbs BP; Kaizer AM; Koopmeiners JS
    J Biopharm Stat; 2021 Nov; 31(6):852-867. PubMed ID: 35129422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic borrowing in the presence of treatment effect heterogeneity.
    Kotalik A; Vock DM; Donny EC; Hatsukami DK; Koopmeiners JS
    Biostatistics; 2021 Oct; 22(4):789-804. PubMed ID: 31977040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.
    Wei W; Blaha O; Esserman D; Zelterman D; Kane M; Liu R; Lin J
    Stat Med; 2024 May; 43(12):2439-2451. PubMed ID: 38594809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A flexible Bayesian framework for individualized inference via adaptive borrowing.
    Ji Z; Wolfson J
    Biostatistics; 2023 Jul; 24(3):669-685. PubMed ID: 35024790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iterated multisource exchangeability models for individualized inference with an application to mobile sensor data.
    Brown R; Fan Y; Das K; Wolfson J
    Biometrics; 2021 Jun; 77(2):401-412. PubMed ID: 32413161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating causal effects from a randomized clinical trial when noncompliance is measured with error.
    Boatman JA; Vock DM; Koopmeiners JS; Donny EC
    Biostatistics; 2018 Jan; 19(1):103-118. PubMed ID: 28605411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Part 2. Development of Enhanced Statistical Methods for Assessing Health Effects Associated with an Unknown Number of Major Sources of Multiple Air Pollutants.
    Park ES; Symanski E; Han D; Spiegelman C
    Res Rep Health Eff Inst; 2015 Jun; (183 Pt 1-2):51-113. PubMed ID: 26333239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Semi-supervised mixture multi-source exchangeability model for leveraging real-world data in clinical trials.
    Haine LMF; Murry TA; Nahra R; Touloumi G; Fernández-Cruz E; Petoumenos K; Koopmeiners JS
    Biostatistics; 2024 Jul; 25(3):617-632. PubMed ID: 37697901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating historical models with adaptive Bayesian updates.
    Boonstra PS; Barbaro RP
    Biostatistics; 2020 Apr; 21(2):e47-e64. PubMed ID: 30247557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empirical shrinkage estimator for consistency assessment of treatment effects in multi-regional clinical trials.
    Quan H; Li M; Shih WJ; Ouyang SP; Chen J; Zhang J; Zhao PL
    Stat Med; 2013 May; 32(10):1691-706. PubMed ID: 22855311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cumulative incidence regression for dynamic treatment regimens.
    Chen LW; Yavuz I; Cheng Y; Wahed AS
    Biostatistics; 2020 Apr; 21(2):e113-e130. PubMed ID: 30371745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Robust exchangeability designs for early phase clinical trials with multiple strata.
    Neuenschwander B; Wandel S; Roychoudhury S; Bailey S
    Pharm Stat; 2016; 15(2):123-34. PubMed ID: 26685103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Bayesian analyses to doubly randomized delayed start, matched control designs to demonstrate disease modification.
    Turkoz I; Sobel M; Alphs L
    Pharm Stat; 2019 Jan; 18(1):22-38. PubMed ID: 30221459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bayesian hierarchical models for adaptive basket trial designs.
    Chen C; Hsiao CF
    Pharm Stat; 2023; 22(3):531-546. PubMed ID: 36625301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian inference of networks across multiple sample groups and data types.
    Shaddox E; Peterson CB; Stingo FC; Hanania NA; Cruickshank-Quinn C; Kechris K; Bowler R; Vannucci M
    Biostatistics; 2020 Jul; 21(3):561-576. PubMed ID: 30590505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamically borrowing strength from another study through shrinkage estimation.
    Röver C; Friede T
    Stat Methods Med Res; 2020 Jan; 29(1):293-308. PubMed ID: 30821201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rediscovery of Good-Turing estimators via Bayesian nonparametrics.
    Favaro S; Nipoti B; Teh YW
    Biometrics; 2016 Mar; 72(1):136-45. PubMed ID: 26224325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-robust estimators: slightly more Bayesian than meets the eye?
    Gustafson P
    Int J Biostat; 2012 Jan; 8(2):. PubMed ID: 22499730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.